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In the clinical practice, many diseases such as glioblastoma, leukemia, diabetes, and prostates have multiple
subtypes. Classifying subtypes accurately using genomic data will provide individualized treatments to
target-specific disease subtypes. However, it is often difficult to obtain satisfactory classification accuracy using only
one type of data, because the subtypes of a disease can exhibit similar patterns in one data type. Fortunately,
multiple types of genomic data are often available due to the rapid development of genomic techniques. This
raises the question on whether the classification performance can significantly be improved by combining multiple
types of genomic data. In this article, we classified four subtypes of glioblastoma multiforme (GBM) with multiple
types of genome-wide data (e.g., mRNA and miRNA expression) from The Cancer Genome Atlas (TCGA) project. We
proposed a multi-class compressed sensing-based detector (MCSD) for this study. The MCSD was trained with data
from TCGA and then applied to subtype GBM patients using an independent testing data. We performed the
classification on the same patient subjects with three data types, i.e., miRNA expression data, mRNA (or gene
expression) data, and their combinations. The classification accuracy is 69.1% with the miRNA expression data,
52.7% with mRNA expression data, and 90.9% with the combination of both mRNA and miRNA expression data. In
addition, some biomarkers identified by the integrated approaches have been confirmed with results from the
published literatures. These results indicate that the combined analysis can significantly improve the accuracy of
classifying GBM subtypes and identify potential biomarkers for disease diagnosis.
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Many diseases including cancers have multiple subtypes.
For example, leukemia has four main categories: acute
lymphoblastic leukemia (ALL), acute myelogenous leu-
kemia, chronic lymphocytic leukemia, and chronic myelo-
genous leukemia. Each of these categories can be further
divided into different subtypes [1]; for example, ALL can
be further subtyped into six types [2]. Glioma has four
subtypes, including oligodendroglioma, anaplastic oligo-
dendroglioma, anaplastic astrocytoma, and glioblastoma
multiforme (GBM) [3]. Prostate cancer has three major
subtypes [4]. An accurate and effective classification of* Correspondence: wyp@tulane.edu
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in any medium, provided the original work is pthose subtypes based on genomic data will result in perso-
nalized treatments of the cancer in terms of a particular
subtype. In this article, we are interested in the subtyping
of GBM, which is a kind of glioma and is the most com-
mon form of malignant brain cancer in adults [5]. There is
an increasing interest in classifying multiple subtypes of
GBM based on its genomic measurements. Most of the
existing works are based on gene expression data only.
Benjamin et al. [6] classified two types of GBM in adults
and found that the genes EGFR and TP53 were important
in discriminating the two subtypes. Nutt et al. [7] built a
k-nearest neighbor model with 20 features to classify 28
glioblastomas and 22 anaplastic oligodendrogliomas and
found that the class distinctions were significantly asso-
ciated with survival outcome (p = 0.05). Noushmehr et al.
[8] separated a subset of samples in GBM from The Cancer
Genome Atlas (TCGA) project, which displayed concertedOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 GBM subtypes and their corresponding samples
used for the training and the testing





These datasets are publically available from the TCGA project.
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we used to subtype GBM are also from TCGA. The sub-
types of GBM samples in TCGA includes: pro-neural,
neural, classical, and mesenchymal [9]. The GBM data we
have tested include both miRNA expression and mRNA
expression data. The miRNAs, also called microRNAs, are
short non-coding RNA molecules that were recently found
in all eukaryotic cells except fungi, algae, and marine plants.
The human genome may contain over 1,000 miRNAs [10].
Aberrant expressions of miRNAs have been found to be
related to many diseases, including cancers [11,12]. They
play an essential role in tissue differentiation during normal
development and tumorigenesis [13].
In the last decade, the development of genomic techni-
ques enables the availability of multiple data types on
the same patient, such as mRNA or gene expression,
SNP, miRNA expression, and copy number variation
data. It is well recognized that a more comprehensive
analysis result could be obtained based on integrating
multiple types of genomic data than using an individual
dataset. Soneson et al. [14] investigated the correlation
between gene expression and copy number alterations
using canonical correlation analysis for leukemia data. A
web-based platform, called Magellan, was developed for
the integrated analysis of DNA copy number and expres-
sion data in ovarian cancer [15], which found significant
correlation between gene expression and patient survival.
Troyanskaya et al. [16] developed a Bayesian framework
to combine heterogeneous data sources to predict gene
function with improved accuracy. A kernel-based statis-
tical learning algorithm was also proposed in the combined
analysis of multiple genome-wide datasets [17]. In this art-
icle, we propose a novel classifier based on the compressed
sensing (CS) theory that we have been working with.
The CS technique enables compact storage and rapid
transmission of large amounts of information. The tech-
nique can be used to extract significant statistical infor-
mation from high-dimensional datasets [18]. The CS
technology has been proven to be a powerful tool in the
signal processing and statistics fields. It demonstrates
that a compressible signal can be recovered from far
fewer samples than that needed by the Nyquist sampling
theorem [19]. Our recent work used a CS-based detector
(CSD) for subtyping leukemia with gene expression data
[20]. The CSD achieved high classification accuracies,
with 97.4% evaluated with cross-validation and 94.3%
evaluated with an independent dataset. The CSD showed
better performance in subtyping two types of leukemia
compared to some traditional classifiers such as the sup-
port vector machine (SVM), indicating the advantage of
the CSD in analyzing high-dimensional genomic data. In
this article, we extended the CSD to multiple data types
and proposed a detector called MCSD. In particular, we
applied the MCSD to the subtyping of four types ofGBM by combining miRNA expression and mRNA ex-
pression data. We present a novel combined analysis
method based on the CS and demonstrate that the clas-
sification performance can significantly be improved in
subtyping four types of GBM, with both miRNA expres-
sion and mRNA expression data.
Methods and materials
Data collection
The GBM data used in this study are publicly available
from the website of TCGA [21]. The patients in the data-
set can be classified into four subtypes, i.e., pro-neural,
neural, classical, and mesenchymal [9]. The genomic data
include miRNA expression (1,510 probes) and mRNA
expression data (22,277 probes). We randomly divided the
data (including 115 patients with both miRNA and mRNA
expression data) into two sets: training and testing data-
sets. The total number of patients in the training dataset
was 60 with 15 patients in each group. The testing dataset
had 55 patients, with 17 pro-neural, 3 neural, 17 classical,
and 18 mesenchymal subtypes (as listed in Table 1). The
same number of patients in each subtype for training data
was used for reducing the bias in the model building.
Meanwhile, the numbers of patients in training and test-
ing were approximately the same.
For multiple types of genomic data (e.g., miRNA expres-
sion data, mRNA expression data, etc.), we used x1i to
denote the data vector for the ith sample in data 1 (e.g.,
miRNA expression), x2i to denote the data vector for the
ith sample in data 2 (e.g., mRNA expression), and xni to
denote the data vector for the ith sample in data n.















To classify a given observation y to one of n classes, we
define the actual class (“ground truth”) to which it belongs
as g; the class to which it is assigned (“decision”) as d. The
n classes are defined as: π1,π2,. . .,πn. Let Uπi (y,g) be the
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is negative relevant to the Bayes Risk (BR) [22], which
is the minimum classification error. Thus, we make:
U = 1-BR. The two-class one-dimensional BR (shaded





p2 yð Þdyþ P1
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p1 yð Þdy; ð1Þ
where y0 is the decision boundary, P1,P2 are the prior
probabilities and P1(y),P2(y) are the conditional probability
density functions of the two classes, respectively (shown
in Figure 1).
Let us extend the BR to n classes and N dimensions.











pj yð Þdy; ð2Þ
where Pj is the prior probability of a given subject
belonging to the class πj, j = 1,. . .,n; Pj(y) is the condi-
tional probability density function of the class πj, and Ωi
is the Bayesian decision region for class πi [23].
For multi-class classification, an ideal detector should
yield
P d ¼ πi g ¼ πj




i ¼ j ;

ð3Þ
where P(d = πi|g = πj) denotes the probability ofFigure 1 Each probability density function is one-dimensional
normal distribution (area under each curve sums to 1).assigning a given observation y, actually belonging to πj,
to πi. δij is the Kronecker’s delta.
According to the ideal observer decision theory [22], a
decision is selected only if its expected utility is greater
than the expected utility of any others. Thus, for any
given observation y, we decide d = πi iff
E Uπi y; gð Þ yj g > E Uπj y; gð Þ yj g; i≠j j ¼ 1; 2; . . . ; i 1; iþ 1; . . . ; n:

ð4Þ
From Equation (2) and the relationship of utility and
BR, we know “utility” is a number that can be calculated.
We denote that number as Ui|j to express the utility of
assigning a given observation y, actually belonging to πj,
to πi. The inequality (4) can be written as
Xn
k¼1
UijkPðg ¼ πk yj Þ>
Xn
k¼1
UjjkPðg ¼ πk yj Þ;
i≠j; j ¼ 1; 2; . . . ; i 1; iþ 1; . . . ; n; :
ð5Þ
We apply Bayes’ rule
Pðg ¼ πk yj Þ ¼ Pyðy g ¼ πkj ÞP g ¼ πkð ÞPy yð Þ ; ð6Þ
where Py(y|g = πk), k = 1,. . .,n, is the probability density
function for the signal observations. According to
Inequality (5), we decide d = πi iff
Xn
k¼1UijkP g ¼ πkð Þpyðy g ¼ πkj Þ>
Xn
k¼1UjjkP g ¼ πkð Þ
py y g ¼ πkj Þ i≠j j ¼ 1; 2; . . . ; i 1; iþ 1; . . . ; n:ð
ð7Þ
That is known as maximum likelihood estimation.











If we assume π1, π2,. . .,πn have the same prior pro-











The calculation of the utility is shown in the Additional
file 1.
Dimension reduction using CS
To reduce the dimension of original sample, we design a
projection (sparse) matrix Φ, called compress matrix.
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as a sparse representation problem as in Equation (10)
Y ¼ ΦS; ð10Þ
where Y ¼ yif g∈RMc is the projected sample, M is the
dimension of the sample after the projection, yi is the ith
column in the compressed signal, c is the total number of
columns in the compressed signal, S ¼ sif g∈RNc is the
original signal, and N is the dimension of the original sig-
nal and N >> M. The matrix Φ∈RMN is a sparse matrix,
with most of the entries ‘0’s. The compress matrix Φ pro-
jects the original sample S to a much smaller dimensional
signal Y. The original sample may contain redundancy;
through this projection, the original sample can signifi-
cantly be compressed and compactly represented, which
usually lead to better classification performance. Suppose
we have n groups, with c1 training samples in group 1, c2
training samples in group 2, and so forth, cn training sam-
ples in group n, and c = c1 + c2 + ··· + cn for S ¼
s1;s2; . . . ; sc
 
∈RNc and Y ¼ y1;y2; . . . ; yc
 
∈RMc . The
transpose of Equation (10) is








c1 denote the jth column of YT, where j = 1,






The linear system given by (12) is an underdetermined
system, which can be solved by using l-1 norm mi-
nimization algorithm such as Homotopy method, or the


















where ‖(ΦT)j‖1 is the l-1 norm of the vector (Φ
T)j, i.e.,
the sum of the absolute values of entries in vector (ΦT)j.
Obviously, the compress matrix Φ projects the original
signal si∈RN1 to a much smaller dimensional signal
Φsi∈RM1. Instead of dealing with the original signal, we
only use Φsi∈RM1 and ΦΦT∈RMM in the subtyping
procedure, leading to a fast classification.
Determination of feature vector
We need to select significant features to represent the ori-
ginal data before we classify the data. For each sample, weextracted five feature characteristics [20]: the mean and
the standard deviation of each group’s standard deviation
(MeanStd, StdStd), the standard deviation of the means of
all the groups (StdMean), and the mean and standard
deviation of Pearson’s linear correlation coefficient (Mean-
Corr, StdCorr) between the samples and their class label
vector. Therefore, for the ith sample, we have a five-
dimensional feature vector as follows:
Vi ¼ MeanStdi; StdStdi; StdMeani;MeanCorriStdCorrif g
where i = 1,2,. . .,N, and N is the number of samples. Each
element in the vector Vi has been normalized by its overall
maximum value so that its value is between 0 and 1, i.e.,
Vi ∈ [0, 1]. A number of M informative features were
selected by setting the threshold values of Vi. If a feature is
informative or significant, we expect that the values from
different patients within the same subtype are similar
while the differences among different subtypes are rela-
tively large. In addition, it is easy to understand that, if the
correlation between the feature vector and the class label
is high, the feature vector can serve as a significant bio-
marker to distinguish the subtypes. According to the
above analysis, matrix Y in Equation (10) is built by those
features with low MeanStd, StdStd, StdCorr while high
StdMean, MeanCorr, which are significant for the
classification.
Classifier based on CS
In this particular study of subtyping four types of GBM
with miRNA expression and mRNA expression data, we
make a hypothesis that the data follow a normal distri-
bution. In other words, the probability density function
for the data is
pyðy^ g ¼ πkj Þ ¼ 2πσ2
 N2 exp 







where y^∈RN is a given observation; s∈RN is the mean of
a sample; and σ is the standard deviation of the data.
After compressing the original sample, the probability
density function (Equation 14) is still Gaussian but with
different mean and standard deviation given by [18]
pyðy g ¼ πkj Þ ¼





 12 2πð ÞN2
ð15Þ
where y^∈RM is a compressed observation; s∈RN is a
known signal and Φ is the compress matrix. The MCSD
used in this study is constructed by substituting Equation
(15) into Equation (9) for maximum likelihood estimation.
The classification algorithm is described as below.
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2. Normalize the rows of the training and the testing
datasets to the range of [0,1]
3. Select informative features according to the feature
selection criteria
4. Calculate compress matrix Φ 2 RMN by the
training dataset by Equation (14)
5. Identify the class of the compressed testing data by
Equation (9), where the probability density function
is given by Equation (15).
There are many other classifiers such as SVM that can
be used. But our purpose here is to show that dimension
reduction with the CS can improve subsequent classifi-
cation and the often used Bayesian classifier is chosen.
Results
We subtyped four types of GBM with multiple genomic
data types (e.g., miRNA expression, mRNA expression,
and their combinations) from TCGA. The MCSD was
first trained by the training data with known class labels,
and was then employed to detect subtypes in another
independent testing dataset. The classification accuracy
by the MCSD was compared with that without using
MCSD. The classification performance between using
the combined data types and using a single type of data
was also compared.
Table 2 shows the comparison of the GBM classifica-
tion accuracy for the testing dataset, with and without
the compress matrix used in our algorithm (see Section
“Methods and materials”). The results were obtained on
three types of data, i.e., miRNA expression data, mRNA
expression data, and their combinations. The classifica-
tion accuracy is defined as the ratio between the number
of correctly labeled samples and the number of total
samples. The result calculated by the non-compressed
detector had a classification accuracy of 41.8% with
miRNA expression data. However, when we used the
MCSD to classify the four subtypes, the accuracy of clas-
sifying the testing dataset was 69.1%, with 54 selected in-
formative features out of 1,510 features. When we tested
the classifiers on the mRNA expression data, the result
calculated by the non-compressed detector was 32.7%.Table 2 Comparison of classification accuracy between












miRNA 69.1 54 41.8
Gene expression 52.7 432 32.7However, the classification result with the MCSD was
52.7%, which employed a subset of the features, 432 out
of 22,277 features.
We also tested if the classification performance of the
MCSD was better than non-compressed detector in the
combined analysis of both miRNA expression and mRNA
expression data as shown in Table 2. The subtyping accur-
acy by the non-compressed detector was 32.7%. The clas-
sification accuracy by the MCSD showed a significant
improvement over the non-compressed detector. The ac-
curacy was 90.9% (121 informative features selected or
145 informative features selected). The 121 features se-
lected are shown in Additional file 2 with the probes and
the corresponding symbols.
Figure 2 demonstrates the classification accuracy when
different numbers of informative features were em-
ployed. The combined analysis of the two types of
genome-wide data was always able to achieve a signifi-
cant higher subtyping accuracy than any single data type
analysis when the same number of informative features
were used (with a subset of features less than 450), indi-
cating the advantages of the combined analysis. Figure 2
also shows that the classification accuracy was low when
only a few features were used, indicating that the subset
was too small to represent the characteristics of the en-
tire dataset. When we increased the number of features
used in the MCSD, the classification accuracy went up.
The accuracy of classifying the testing dataset reached
the highest value, 69.1, 52.7, and 90.9% on the miRNA
expression, mRNA expression, and their combinations,
respectively. However, more features may also add
redundancy and thus cause the decrease of the classifica-
tion accuracy. Therefore, we conclude that the use ofFigure 2 The comparison of the classification accuracies
between the combined analysis and the single data type
analysis. All of them employed MCSD method to subtype four types
of GBM. Note that a significant improvement of the classification
accuracy has been achieved by using the combined analysis.
ba
Figure 3 (See legend on next page.)
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Figure 3 Display of the selected features in distinguishing the four subtypes of GBM, i.e., pro-neural (P), neural (N), classical (C), and
mesenchymal (M) for the testing dataset (a) and the training dataset (b). 121 features (3 miRNA expression probes on the top and followed
by 118 mRNA expression probes) were chosen from both miRNA expression and mRNA expression data. Each row represents a feature and each
column represents a sample/patient. Each feature is normalized by the largest value in each row. The samples with arrows were misclassified to
the subtypes as denoted by the arrow.
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cation accuracy.
Figure 3a displays the normalized levels of the 121
selected features (118 mRNAs and 3 miRNAs) from
both miRNA expression and mRNA expression data for
the combined analysis, with the highest classification ac-
curacy of 90.9%. If using the mRNA and miRNA data
separately, they only give the accuracy as 49.1 and
47.3%, respectively. The samples with arrows were mis-
classified to the subtypes pointed by the arrows (e.g., the
17th sample that belongs to pro-neural was misclassified
to classical). Each column represents a patient/sample
and each row represents a feature (a probe from miRNA
expression or mRNA expression data). The four sub-
types of GBM are pro-neural, neural, classical, and mes-
enchymal. Each feature was normalized by the largest
value in each row. It can be found that the misclassifica-
tion only happens among the subtypes of pro-neural,
neural, and classical. The number of misclassified sam-
ples in each subtype is one sample in pro-neural, two
samples in neural, two samples in classical, and zero
samples in mesenchymal. The expression levels in the
subtype mesenchymal exhibit a significant difference from
other three subtypes as shown in Figure 3a. Figure 3b dis-
plays the same selected features in the training dataset.
Conclusion and discussion
In this study, we applied the proposed MCSD to subtype
four types of GBM: pro-neural, neural, classical, and
mesenchymal with multiple genetic data from TCGA.
High classification accuracy was achieved by using CS-
based technique (i.e., MCSD) along with the combin-
ation of multiple datasets. The results from combining
two types of genomic data were compared with those
from single type of data. Moreover, the performance of
the classification with and without MCSD technique had
also been compared. The comparisons showed that the
CS-based combined analysis of multiple types of genetic
data could significantly improve the accuracy of detect-
ing GBM subtypes.
Combining different types of genomic data allows us to
interpret the information in the datasets comprehensively.
The information from miRNA and mRNA are comple-
mentary to each other; so a combined analysis can give a
better result than single data type analysis. miRNAs are a
recently discovered class of small non-coding RNAs that
regulate gene expression [25], which can be combinedwith mRNA data for better disease subtyping. However, if
no dimension reduction with CS was applied, we found
from Table 2 that the classification accuracy from com-
bined analysis was comparable to that from the single
mRNA expression because of the redundancy added. The
classification performance was significantly improved after
we used CS method, indicating that CS may reduce
redundancy [26] in the combined datasets and thus im-
prove the classification accuracy.
Informative features/biomarkers selected in this study
have also been validated to be associated with GBM and
have been reported in the literatures. In the combined
data analysis, the 121 features/probes selected (shown in
Additional file 2), the 3 miRNA expression probes and 118
mRNA expression probes are listed. Two of the selected
miRNAs probes that represent the same miRNA, “hsa-
miR-9” (sequence “TCATACAGCTAGATAACCAA”), have
been validated to have stemness potential and chemoresis-
tance to GBM cells [27-29], and known to be specifically
expressed during brain neurogenesis. In the listed mRNA
expression probes, the four probes of “CD44” and the three
probes of “ASCL1” are selected. Both of the genes have
been validated as biomarkers in subtyping GBM in multiple
genomic studies [9,30-32]. It demonstrates the significance
of “CD44” and “ASCL1” in discriminating different sub-
types of GBM. The three probes from “THBS1” are also
selected in the 121 probes list. “THBS1” is a subunit of a
disulfide-linked homotrimeric protein. This protein has
been shown to play roles in platelet aggregation, angiogen-
esis, and tumorigenesis [33]. “THBS1” is also a major acti-
vator of “TGFB1” and the “TGFB1” expression is associated
with GBM [34]. Moreover, it has been found that “TbRII”,
a receptor of “TGFB1”, has a strong relationship with
human malignant glioblastoma cells [35]. There are bio-
markers listed in Additional file 2 that have not been
reported yet. However, they may be potential biomarkers
for GBM, deserving further study.
We also performed Gene Ontology (GO) analyses to de-
termine that these genes were enriched in specific GO
terms (biological processes). The GO term “antigen proces-
sing” and presentation “lymphocyte mediated immunity”
(p = 1.78 × 10–6), and several GO terms related to wound-
ing healing [e.g. “response to wounding” (p = 1.26 × 10–8);
“wound healing” (p = 2.44 × 10–6)], and cell adhesion
[e.g. “biological adhesion” (p = 6.53 × 10–7); “cell adhesion”
(p = 6.41 × 10–7)] showed highly significant enrichment for
our selected genes. These results were expected. Taking
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an example, lymphocyte-mediated cellular responses play a
critical role in the body’s ability to generate an antitumor
immune response, and activation status of lymphocytes is
an important determinant of sensitivity to tumor-mediated
apoptosis [36]. In addition, according to previous studies,
the miRNAs we identified are related to glioblastoma.
For example, it was found that “has-miR-9” inhibit
differentiation of glioblastoma stem cells, and the cal-
modulin-binding transcription activator 1 (CAMTA1)
as “has-miR-9” target is a tumor suppressor in glio-
blastoma [37].
To test the stability of the classification results, the
samples in training and testing were randomly rear-
ranged ten more times. The number of samples from
each subtype in training and testing was maintained the
same as in the description in the section “Data collec-
tion”. The overall classification rate has an average value
of 87.1% with a standard deviation of 4.5%, indicating
that the results are rather robust.
In summary, we have developed a CS-based technique
for combining multiple genomic data to subtype glio-
blastoma more accurately. The biomarkers identified
with our approaches have also been validated or re-
ported in some existing literatures, indicating that the
integrated approach can provide comprehensive infor-
mation for better disease diagnosis.Additional files
Additional file 1: Calculation of U for the MCSD.
Additional file 2: List of 121 selected features.Competing interests
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